Tarsus Pharmaceuticals Reports Strong Full-Year 2025 XDEMVY Sales, Reduced Losses, and $2B+ Peak Sales Outlook
Summary
Tarsus Pharmaceuticals announced robust full-year 2025 financial results, driven by over 150% growth in XDEMVY net product sales to $451.4 million, significantly reducing its net loss and projecting over $2 billion in peak sales for the product.
Key Events
-
Record XDEMVY Sales
Full-year 2025 net product sales of XDEMVY reached $451.4 million, marking over 150% year-over-year growth, with Q4 2025 sales at $151.7 million.
-
Reduced Net Loss
The company significantly narrowed its full-year net loss to $66.4 million in 2025, down from $115.6 million in 2024, and Q4 net loss to $8.4 million from $23.1 million in the prior year.
-
Strong Peak Sales Outlook
Management projects XDEMVY's peak sales potential to exceed $2 billion, highlighting long-term commercial confidence.
-
Pipeline Advancement
Tarsus initiated a Phase 2 trial for TP-04 in ocular rosacea and plans to start a Phase 2 trial for TP-05 in Lyme disease prevention in Q2 2026.
Analysis
This 8-K details a highly positive earnings report for Tarsus Pharmaceuticals. The substantial year-over-year growth in XDEMVY sales, coupled with a significant reduction in net loss, indicates strong commercial execution and improving financial health. The company's confidence in XDEMVY's peak sales potential exceeding $2 billion provides a strong long-term growth narrative. Additionally, the advancement of its pipeline with new Phase 2 trials for ocular rosacea and Lyme disease prevention demonstrates continued investment in future growth drivers. Investors should view these results as a strong validation of the company's strategy and commercialization efforts.
At the time of this filing, TARS was trading at $69.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $38.51 to $85.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.